⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Canagliflozin

کاناگلیفلوزین

⚠ Unverified

🍽️ Alimentary Tract And MetabolismSGLT2 inhibitor

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA204042 ATC A10BK02

Market / country: 🇺🇸 USA

Invokana (US)

🧮 Dose calculator

Disease / regimen

Type 2 diabetes mellitus · Regimen source: FDA Invokana · 2.2

• Correct volume depletion first. Withhold ≥3 days before surgery. With UGT inducers (rifampin, phenytoin…) increase to 200 mg. FDA Invokana · 2.1 FDA Invokana · 2.5 FDA Invokana · 2.4

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Serious hypersensitivity to canagliflozin (anaphylaxis, angioedema). FDA Invokana · 4

Warnings

• Ketoacidosis (even with modest glucose); lower-limb amputation; volume depletion; genitourinary infections incl. urosepsis; hypoglycaemia with insulin or sulfonylureas. FDA Invokana · 5
• Bone fracture. FDA Invokana · 5.7

Renal adjustment

• eGFR < 60: eGFR 30–<60: max 100 mg. Below 30: initiation not recommended (may continue 100 mg if albuminuria >300 mg/day). FDA Invokana · 2.3

Formulations

100 mg tablet — tablet 🇺🇸 USA FDA Invokana · 3
300 mg tablet — tablet 🇺🇸 USA FDA Invokana · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Invokana · 8.1
“Risk Summary Based on juvenile animal data showing adverse renal effects, INVOKANA is not recommended during the second and third trimesters of pregnancy.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Invokana · 8.2
“Risk Summary There is no information regarding the presence of INVOKANA in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Invokana · 8.4
“The safety and effectiveness of INVOKANA as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus have been established in pediatric patients aged 10 years and older.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Invokana · 8.5
“Patients 65 years and older had a higher incidence of adverse reactions related to reduced intravascular volume with INVOKANA (such as hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration), particularly with the 300 mg daily dose, compared to younger patients; a more prominent increase in …”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA204042
DailyMed (FDA label)FDA Invokana
MedlinePlus (NIH)Canagliflozin
WHO ATC/DDDA10BK02
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Invokana · 3 FDA Invokana · 2.2 FDA Invokana · 2.1 FDA Invokana · 2.5 FDA Invokana · 2.4 FDA Invokana · 2.3 FDA Invokana · 4 FDA Invokana · 5 FDA Invokana · 5.7 FDA Invokana · SPL approval / marketing category FDA Invokana · 8.1 FDA Invokana · 8.2 FDA Invokana · 8.4 FDA Invokana · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified